Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Pheast Therapeutics
Eli Lilly and Company
Nested Therapeutics, Inc
EMD Serono
Novartis
Iambic Therapeutics, Inc
Jecho Biopharmaceuticals Co., Ltd.
Ariceum Therapeutics GmbH
Hutchmed
Boston Scientific Corporation
Pfizer
Pfizer
Tcelltech Inc.
Orano Med LLC
Tetragon Biosciences Ltd
Cellectar Biosciences, Inc.
RasCal Therapeutics, Inc.
Cellectar Biosciences, Inc.
Beijing Biotech
Boehringer Ingelheim
Novartis
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Servier
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Novartis
Ipsen
AstraZeneca
CureVac
Servier
Servier
Servier
Daiichi Sankyo
Novartis
AstraZeneca
Chimeric Therapeutics
EMD Serono
Alpha Biopharma (Jiangsu) Co., Ltd.
GlaxoSmithKline
Telix Pharmaceuticals (Innovations) Pty Limited
Duke Street Bio Ltd
Neonc Technologies, Inc.
Novartis
AstraZeneca
Jazz Pharmaceuticals
ITM Solucin GmbH
Degron Therapeutics Co.
Pasithea Therapeutics Corp.
VPIX Medical
Pfizer